Chinese investigators have published data from studies investigating CYT-997 for the treatment of hypertrophic scars. CYT-997 is a tubulin polymerization inhibitor that reached phase II clinical development for the treatment of multiple myeloma and glioblastoma multiforme.
French biotech Pep-Therapy SAS is in the midst of raising a €20 million (US$21.62 million) round and, at the same time, prospecting for potential partners after winning FDA orphan drug designation for its bifunctional peptide Pep-010 in the treatment of pancreatic cancer. Pep-010 currently is moving to the conclusion of a phase Ib trial and the new money will fund phase II development.
China’s National Medical Products Administration (NMPA) has accepted Ascentage Pharma Group Corp. Ltd.’s NDA for its in-house-developed Bcl-2 selective inhibitor, lisaftoclax (APG-2575), which could be the first domestically approved Bcl-2 inhibitor in China and the second global approval.
Resistance to radiotherapy is a crucial factor in the outcome of colorectal cancer (CRC). The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway plays a key role in cell growth, differentiation, proliferation and immune function.
Bladder cancer is characterized by a high recurrence rate, with limited therapeutic options available. There is a need to discover new therapeutic targets and approaches to overcome this.
Researchers from the University of Minnesota and collaborators have synthesized and evaluated a novel series of antiproliferative benzofuran derivatives that led to the identification of [I] as the most potent candidate.
Integrated Biosciences Inc., an early-stage startup that is combining synthetic biology and machine learning in the hunt for drugs that tackle cell senescence, has demonstrated its capabilities in a newly published study in Nature Aging on May 4, 2023, which employed artificial intelligence to identify three novel compounds that are highly selective for Bcl-2 and that exhibit favorable medicinal chemistry profiles.
Integrated Biosciences Inc., an early-stage startup that is combining synthetic biology and machine learning in the hunt for drugs that tackle cell senescence, has demonstrated its capabilities in a newly published study in Nature Aging on May 4, 2023, which employed artificial intelligence (AI) to identify three novel compounds that are highly selective for Bcl-2 and that exhibit favorable medicinal chemistry profiles.
The controlled cell death process of apoptosis functions as the first step to any full recovery from injury or disease. In the second step of any recovery process, dead cells are cleared by efferocytosis, a process performed by phagocytotic cells like macrophages. Approximately 200-300 billion apoptotic cells are cleared daily by efferocytosis starting with the recognition of newly extracellular facing phosphatidylserine (PtdSer) by PtdSer-binding proteins present on phagocytotic cells.
